research reports and media, page-448

Even for me, when I initially first heard of PAR - I ruled it out - for the same reason most funds ignore companies in clinical trials - trying to pick a winner is a crapshoot for most people except perhaps doctors, scientists and other medical scientists that work in the field. I've had a go at it in the past, in particular with SRX.

This is a view that is also stated recently by John Hempton from Bronte Capital:

“Almost nobody understands the science behind most biotech long-shots,” the letter says.
“Biotechnology itself is so specialised that, unless one’s PhD is directly in the area, one’s understanding is probably too limited to really understand the putative drug and its prospects.
“Almost everyone – including most of the experts – are shooting in the dark.
Biotech offers promoters the chance to sell worthless or nearly worthless lottery tickets to gamblers.”

However, upon a closer look, I realised Zilosul is not your average new, unknown, untested drug which got me interested and now here I am, for better or for worse..